BOLT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BOLT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Bolt Biotherapeutics's average Accounts Receivable for the three months ended in Sep. 2024 was $0.00 Mil. Bolt Biotherapeutics's Revenue for the three months ended in Sep. 2024 was $1.14 Mil. Hence, Bolt Biotherapeutics's Days Sales Outstanding for the three months ended in Sep. 2024 was 0.00.
The historical rank and industry rank for Bolt Biotherapeutics's Days Sales Outstanding or its related term are showing as below:
Bolt Biotherapeutics's Days Sales Outstanding stayed the same from Sep. 2023 (0.00) to Sep. 2024 (0.00).
The historical data trend for Bolt Biotherapeutics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bolt Biotherapeutics Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Days Sales Outstanding | Get a 7-Day Free Trial | - | - | - | - | - |
Bolt Biotherapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Days Sales Outstanding | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Bolt Biotherapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Bolt Biotherapeutics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Bolt Biotherapeutics's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Accounts Receivable can be measured by Days Sales Outstanding.
Bolt Biotherapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as
Days Sales Outstanding (A: Dec. 2023 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Dec. 2022 ) | + | Accounts Receivable (A: Dec. 2023 )) | / | count ) | / | Revenue (A: Dec. 2023 ) | * | Days in Period |
= | ( (0 | + | 0) | / | 1 ) | / | 7.876 | * | 365 |
= | 0 | / | 7.876 | * | 365 | ||||
= | 0.00 |
Bolt Biotherapeutics's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:
Days Sales Outstanding (Q: Sep. 2024 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Jun. 2024 ) | + | Accounts Receivable (A: Sep. 2024 )) | / | count ) | / | Revenue (A: Sep. 2024 ) | * | Days in Period |
= | ( (0 | + | 0) | / | 1 ) | / | 1.141 | * | 365 / 4 |
= | 0 | / | 1.141 | * | 365 / 4 | ||||
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bolt Biotherapeutics (NAS:BOLT) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Thank you for viewing the detailed overview of Bolt Biotherapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.
William P. Quinn | officer: Chief Financial Officer | SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO CA 94080 |
Edgar Engleman | director | 575 HIGH STREET, STE 201, PALO ALTO CA 94301 |
Vivo Capital Fund Viii, L.p. | 10 percent owner | 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301 |
Laura Berner | director | C/O BOLT BIOTHERAPEUTICS, INC., 900 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063 |
Novo Holdings A/s | 10 percent owner | TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
James Healy | director | 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025 |
Brian O'callaghan | director | 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921 |
Frank D. Lee | director | C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472 |
Kathleen Laporte | director | |
Miller Richard A Md | director | PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521 |
Mahendra Shah | director | 2250 HOLCOMBE BLVD, HOUSTON TX 77030 |
Grant Yonehiro | officer: Chief Business Officer | C/O MAXYGEN, INC., 515 GALVESTON DRIVE, REDWOOD CITY CA 94063 |
Randall C Schatzman | director, officer: Chief Executive Officer | 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011 |
David Dornan | officer: Chief Scientific Officer | C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTON DRIVE, REDWOOD CITY CA 94063 |
Edith A. Perez | officer: Chief Medical Officer | C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTONE DRIVE, REDWOOD CITY CA 94063 |
From GuruFocus
By PRNewswire • 08-27-2024
By PRNewswire • 08-26-2024
By Marketwired • 08-28-2024
By Business Wire • 09-02-2024
By PRNewswire • 09-03-2024
By Marketwired • 11-12-2024
By PRNewswire • 08-31-2024
By GuruFocus News • 10-22-2024
By GuruFocus News • 10-07-2024
By Marketwired • 09-04-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.